Immutep To Present At The Jefferies Virtual Healthcare Conference

Rhea-AI Summary

Immutep Limited (NASDAQ: IMMP) announced that CEO Marc Voigt will present at the Jefferies Virtual Healthcare Conference from June 1-4, 2021. The corporate presentation, alongside Chief Scientific and Medical Officer Dr. Frederic Triebel, is scheduled for June 4 at 12:30 PM ET. A live webcast will be available for the event. Immutep is focused on developing immunotherapy treatments for cancer and autoimmune diseases, with its lead product candidate being eftilagimod alpha (IMP321), which activates antigen presenting cells.

SYDNEY, AUSTRALIA, May 25, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, announced today that Immutep CEO Marc Voigt has been invited to participate in the Jefferies Virtual Healthcare Conference, which is taking place from June 1^st to 4^th.

During this virtual conference, Mr. Voigt is scheduled to conduct a corporate presentation followed by a Q&A session along with Immutep’s Chief Scientific and Medical Officer, Dr. Frederic Triebel, starting at 12:30 pm ET on June 4^th. A live webcast of this event will be available at
https://wsw.com/webcast/jeff174/immp/1858869

Further details about the Jefferies Virtual Healthcare Conference can be found at
https://www.jefferies.com/IdeasAndPerspectives/Conferences/325/060821

About Immutep
Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep’s large pharmaceutical partners.

Further information can be found on the Company’s website www.immutep.com or by contacting:

Australian Investors/Media:
Catherine Strong, Citadel-MAGNUS
+61 (0)406 759 268; cstrong@citadelmagnus.com

U.S. Media:
Tim McCarthy, LifeSci Advisors
+1 (212) 915.2564; tim@lifesciadvisors.com

FAQ

When will Immutep's CEO present at the Jefferies Virtual Healthcare Conference?

Immutep's CEO Marc Voigt will present on June 4, 2021, at 12:30 PM ET.

What is the main focus of Immutep Limited?

Immutep Limited focuses on developing immunotherapy treatments for cancer and autoimmune diseases.

What is the lead product candidate of Immutep?

Immutep's lead product candidate is eftilagimod alpha (IMP321), a soluble LAG-3 fusion protein.

How can I watch the presentation of Immutep at the conference?

The presentation will be available via a live webcast at the Jefferies Virtual Healthcare Conference.

What dates does the Jefferies Virtual Healthcare Conference take place?

The Jefferies Virtual Healthcare Conference takes place from June 1 to June 4, 2021.